Journal
CELL STEM CELL
Volume 22, Issue 6, Pages 834-849Publisher
CELL PRESS
DOI: 10.1016/j.stem.2018.05.013
Keywords
-
Categories
Funding
- National Eye Institute (NEI), Bethesda, MD, USA [NEI 01EY022079]
- Empire State Stem Cell Fund through New York State Department of Health [C028504]
- Regenerative Research Foundation
- Macular Vision Research Foundation [I01-BX002950]
- UK Medical Research Council
- European Research Council [ERC-2012-ADG_20120314]
- RP Fighting Blindness
- Carol and Dick Hertzberg Fund
- Richard Annesser Fund
- MRC [MR/J004553/1, MR/M007871/1] Funding Source: UKRI
Ask authors/readers for more resources
Ocular regenerative therapies are on track to revolutionize treatment of numerous blinding disorders, including corneal disease, cataract, glaucoma, retinitis pigmentosa, and age-related macular degeneration. A variety of transplantable products, delivered as cell suspensions or as preformed 3D structures combining cells and natural or artificial substrates, are in the pipeline. Here we review the status of clinical and preclinical studies for stem cell-based repair, covering key eye tissues from front to back, from cornea to retina, and including bioengineering approaches that advance cell product manufacturing. While recognizing the challenges, we look forward to a deep portfolio of sight-restoring, stem cell-based medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available